Introduction
============

For several decades, bypass surgery has been regarded as the treatment of choice for patients with unprotected left main coronary artery (LMCA) disease.^[@b1]--[@b2]^ However, because of easy anatomic accessibility and a relatively large vessel caliber, left main percutaneous coronary intervention (PCI) for LMCA disease has become an attractive option for cardiologists. In addition, technical advances in PCI and stent technology have emboldened physicians to test the feasibility of LMCA intervention and, coupled with the widespread availability of drug‐eluting stents (DESs), has led to reevaluation of the role of PCI as a viable alternative treatment for unprotected LMCA disease.^[@b3]^ As a result, during the last decade, the prevalence of LMCA stenting has significantly increased worldwide. In addition, several recent large registries^[@b4]--[@b13]^ and randomized controlled trials^[@b14]--[@b17]^ have demonstrated that LMCA stenting yields mortality and morbidity rates comparable to coronary artery bypass grafting (CABG).

Hence, it is timely to now move the discussion forward on how to optimize PCI results, beyond the feasibility and safety issues with LMCA stenting. In this review, we briefly summarize the current status of LMCA stenting and discuss the concept of optimal LMCA stenting through integrated use of fractional flow reserve (FFR) and intravascular ultrasound (IVUS).

Current Status of LMCA Stenting
===============================

On the basis of increasing off‐label experiences with stenting and clinical studies,^[@b4]--[@b22]^ the American Heart Association/American College of Cardiology^[@b23]^ and the European Society of Cardiology and the European Association for Cardio‐Thoracic Surgery.^[@b24]^ recently updated the PCI guideline for the elective treatment of LMCA stenosis to include class IIa indications with a B level of evidence depending on the anatomical complexity of the coronary artery disease. Therefore, DES implantation is currently considered an alternative option for selected patients with unprotected LMCA disease. [Table 1](#tbl01){ref-type="table"} summarizes key observational studies, meta‐analyses, and randomized trials that compare PCI with DES and CABG.^[@b4]--[@b22]^ Detailed guidelines are summarized in [Table 2](#tbl02){ref-type="table"}. However, many unresolved technical issues remain, including how to assess the functional significance of intermediate LMCA stenosis and how to optimize procedural outcomes, especially for LMCA bifurcation lesion PCI. In this regard, daily practice has already changed to include more use of FFR and IVUS for LMCA stenting.^[@b25]--[@b26]^

###### 

Key Comparative Studies of PCI and CABG for Left Main Disease

  --------------------------------------------------------------------------------------------------------------------------------------------------------------
  Design                        Contributing Studies   PCI (n)   CABG (n)       Follow‐up Duration        Adjusted Risk for Death    Adjusted Risk for TVR/TLR
  ----------------------------- ---------------------- --------- -------------- ------------------------- -------------------------- ---------------------------
  Observational study           MAIN‐COMPARE[@b4]      784       690            5 years                   HR 1.00 (0.73 to 0.37)\    HR 6.45 (3.75 to 11.09)\
                                                                                                          *P*=0.99                   *P*=0.34

  Lee et al[@b5]                153                    50        6.7 months     4% for PCI\               7% for PCI\                
                                                                                13% for CABG\             1% for CABG\               
                                                                                *P*=0.18                  *P*=0.22                   

  Chieffo et al[@b6]            107                    142       1 year         OR 0.33 (0.06 to 1.40)\   OR 4.22 (1.49 to 14.55)\   
                                                                                *P*=0.17                  *P*=0.005                  

  Palmerini et al[@b7]          94                     154       1.2 years      HR 0.99 (0.47 to 2.07)\   25.5% for PCI\             
                                                                                *P*=0.97                  2.6% for CABG\             
                                                                                                          *P*=0.0001                 

  Sanmartin et al[@b8]          96                     245       1 year         5.2% for PCI\             5.2% for PCI\              
                                                                                8.4% for CABG\            0.8% for CABG\             
                                                                                *P*=0.34                  *P*=0.004                  

  Makikallio et al[@b9]         49                     238       1 year         4% for PCI\               4% for PCI\                
                                                                                11% for CABG\             2% for CABG\               
                                                                                *P*=0.14                  *P*=0.29                   

  Cheng et al[@b10]             94                     216       3 years        12.1% for PCI\            16.0% for PCI\             
                                                                                21.1% for CABG\           6.1% for CABG\             
                                                                                *P*=0.01                  *P*=0.002                  

  Wu et al[@b11]                131                    245       3 years        HR 0.22 (0.06 to 0.81)\   HR 2.69 (1.30 to 5.57)\    
                                                                                *P*=0.02                  *P*=0.008                  

  Park et al[@b12]              205                    257       3 years        OR 1.20 (0.70 to 2.08)\   OR 5.56 (2.85 to 10)\      
                                                                                *P*=0.51                  *P*\<0.001                 

  CUSTOMIZE[@b13]               222                    361       1 year         HR 1.1 (0.4 to 3.0)\      HR 8.0 (2.2 to 28.7)\      
                                                                                *P*=0.81                  *P*=0.001                  

  Meta‐analysis                 Takagi et al[@b19]     1006      1175           3 months to 3 years       OR 0.99 (0.69 to 1.43)\    OR 5.05 (3.07 to 8.30)\
                                                                                                          *P*=0.97                   *P*\<0.001

  Lee et al[@b20]               1236                   1669      1 year         OR 0.83 (0.64 to 1.25)    OR 2.27 (1.69 to 3.13)     

  Naik et al[@b21]              1659                   2114      1 to 3 years   OR 1.27 (0.83 to 1.94)    OR 3.30 (0.96 to 11.33)    

  Capodanno et al[@b22]         809                    802       1 year         OR 0.74 (0.43 to 1.29)\   OR 2.25 (1.54 to 3.29)\    
                                                                                *P*=0.29                  *P*\<0.001                 

  Randomized controlled trial   Buzman et al[@b14]     52        53             1 year                    1.9% for PCI\              9.7% for PCI\
                                                                                                          7.5% for CABG\             9.4% for CABG\
                                                                                                          *P*=0.37                   *P*=0.97

  SYNTAX substudy[@b15]         357                    348       1 year         4.2% for PCI\             6.5% for PCI\              
                                                                                4.4% for CABG\            11.8% for CABG\            
                                                                                *P*=0.88                  *P*=0.02                   

  Boudriot et al[@b16]          100                    101       1 year         5.0% for PCI\             5.9% for PCI\              
                                                                                7.98% for CABG            14.0% for CABG             

  Park et al[@b17]              300                    300       1 year         4.4% for PCI\             9.0% for PCI\              
                                                                                4.7% for CABG\            4.2% for CABG\             
                                                                                *P*=0.83                  *P*=0.02                   
  --------------------------------------------------------------------------------------------------------------------------------------------------------------

PCI indicates percutaneous coronary intervention; CABG, coronary artery bypass grafting; TVR, target‐vessel revascularization; TLR, target‐lesion revascularization; SYNTAX, the Synergy between PCI with Taxus and Cardiac Surgery.

###### 

ACC/AHA and ESC Guidelines for Elective PCI for Unprotected Left Main Coronary Artery Disease

  Guidelines                                                                                                                                                                                                                                    COR                                                      LOE
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------- -----
  2011 ACC/AHA Guidelines[@b23]                                                                                                                                                                                                                 IIa---For SIHD when both of the following are present:   
  Anatomic conditions associated with a low risk of PCI procedural complications and a high likelihood of good long‐term outcome (eg, a low SYNTAX score of ≤22, ostial or trunk left main stenosis)                                            B                                                        
  Clinical characteristics that predict a significantly increased risk of adverse surgical outcomes (eg, STS‐predicted risk of operative mortality ≥5%)                                                                                                                                                  
  IIb---For SIHD when both of the following are present:                                                                                                                                                                                                                                                 
  Anatomic conditions associated with a low to intermediate risk of PCI procedural complications and an intermediate to high likelihood of good long‐term outcome (eg, low‐intermediate SYNTAX score of \<33, bifurcation left main stenosis)   B                                                        
  Clinical characteristics that predict an increased risk of adverse surgical outcomes (eg, moderate‐severe COPD, disability from prior stroke, or prior cardiac surgery; STS‐predicted risk of operative mortality \>2%)                                                                                
  III---For SIHD in patients (vs performing CABG) with unfavorable anatomy for PCI and who are good candidates for CABG                                                                                                                         B                                                        
  2010 ESC Guidelines[@b24]                                                                                                                                                                                                                     IIa---Left main (isolated or 1VD, ostium/shaft)          B
  IIb---Left main (isolated or 1VD, bifurcation)/left main+2VD or 3VD, SYNTAX score ≤32                                                                                                                                                         B                                                        
  IIIb---Left main+2VD or 3VD, SYNTAX score ≥33                                                                                                                                                                                                 B                                                        

ACC indicates American College of Cardiology; AHA, American Heart Association; ESC, European Society of Cardiology; PCI, percutaneous coronary intervention; COR, class of recommendation; LOE, level of evidence; SIHD, stable ischemic heart disease; SYNTAX, the Synergy between PCI with Taxus and Cardiac Surgery; STS, Society of Thoracic Surgeons; COPD, chronic obstructive pulmonary disease; CABG, coronary artery bypass graft; VD, vessel disease.

Why Should We Consider FFR in Intermediate LMCA Stenosis?
=========================================================

Identification of significant stenosis of LMCA is of critical prognostic importance. Nevertheless, an angiographic stenosis diameter of 50% is still considered a cutoff value for significant LMCA stenosis. Hamilos et al^[@b27]^ were the first to demonstrate the considerable discrepancy between coronary angiography and fractional flow reserve (FFR) in the evaluation of intermediate LMCA stenosis. Among the 213 patients in their study, 62 patients (29.1%) showed a "visual functional mismatch" between angiographic significance and functional significance, 13 patients had a diameter stenosis \>50% while the FFR was \>0.80, and 49 patients had a diameter stenosis \<50% while the FFR was \<0.80. It is interesting to note that the prevalence of "reverse mismatch," which refers to angiographically insignificant but functionally significant stenosis, was dominant and as high as 79.0% among the mismatched patients. [Figure 1](#fig01){ref-type="fig"} demonstrates the discrepancy between coronary angiography and FFR.

![Representative case of visual--functional mismatch in LMCA stenosis. A, Visually estimated percentage diameter stenosis was ≈60%, but FFR was 0.86. B, Visually estimated percentage diameter stenosis was ≈20%, but FFR was 0.70. LM indicates left main; MLA, minimal lumen area; FFR, fractional flow reserve; LMCA, left main coronary artery.](jah3-1-e004556-g1){#fig01}

In addition, noninvasive functional testing such as myocardial perfusion imaging is often noncontributive in the diagnosis of patients with intermediate LMCA stenosis. Perfusion defects are often seen in only 1 vascular territory, or tracer uptake may be reduced in all vascular territories ("balanced ischemia") giving rise to false‐negative studies, especially when the right coronary artery is significantly diseased.^[@b28]^ This is another reason why we should measure FFR for intermediate LMCA stenosis.

Therefore, the decision about whether the treatment of intermediate LMCA stenosis should be performed or deferred should not be determined by coronary angiogram alone, and FFR measurement for intermediate LMCA evaluation should be required, especially in cases of ostial and shaft LMCA disease. FFR measurement could avoid unnecessary LMCA stenting or bypass surgery. Revascularization of a nonsignificant stenosis in the LMCA may lead to early occlusion of the conduits, especially when internal mammary arteries are used.^[@b29]^ In addition, when significant LMCA stenosis is highly suspected in a noninvasive functional study in patients with angiographically mild LMCA stenosis, FFR measurement reduced the risk that functionally significant LMCA stenosis remained unrevascularized.

FFR\>0.80 Is a Good Predictor of Favorable Prognosis in Intermediate LMCA Stenosis
==================================================================================

An FFR\>0.75 to 0.80 has been suggested as a strong predictor of favorable survival and low event rates in patients with intermediate LMCA disease, making it useful for the identification of patients in whom deferral of revascularization is associated with favorable clinical outcomes. In an evaluation of patients with intermediate LMCA stenosis, patients with an FFR≥0.80 treated medically had survival rates comparable to patients with an FFR\<0.80 who underwent CABG. Therefore, FFR‐guided decision making for the treatment of intermediate LMCA stenosis is associated with favorable prognosis, and intermediate LMCA disease with an FFR≥0.75 to 0.80 could be safely deferred. [Table 3](#tbl03){ref-type="table"} summarizes key studies that demonstrate FFR‐guided decision making in intermediate LMCA stenosis stenosis.^[@b27],[@b30]--[@b33]^

###### 

Clinical Outcomes of LMCA Stenosis Managed by FFR‐Guided Decision Making

                                 Hamilos et al[@b27]   Bech et al[@b30]                              Courtis et al[@b31]   Lindstaedt et al[@b32]                        Jasti et al[@b33]                                                                                                                                                                  
  ------------------------------ --------------------- --------------------------------------------- --------------------- --------------------------------------------- ----------------------------------------- ------------ ----------------------------------------- --------------------------------------------- ----------------------------------- ---------------------------------------------
  Age, y                         64±9                  68±11                                         63±9                  60±9                                          61±10                                     63±10        61±10                                     64±9                                          62±11                               
  Mean follow‐up, months         35±25                 29±15                                         13±10                 14±12                                         29±18                                     29±14        38                                                                                                                          
  No. of patients                75                    138                                           30                    24                                            60                                        82           27                                        24                                            14                                  37
  FFR cutoff value               \<0.80                ≥0.80                                         \<0.75                ≥0.75                                         \<0.75[\*](#tf3-1){ref-type="table-fn"}   \>0.80       \<0.75[\*](#tf3-1){ref-type="table-fn"}   \>0.80                                        \<0.75                              ≥0.75
  Treatment                      CABG                  Medication[\*](#tf3-2){ref-type="table-fn"}   CABG                  Medication[\*](#tf3-2){ref-type="table-fn"}   Revascularization (CABG 54, PCI 6)        Medication   CABG                                      Medication[\*](#tf3-2){ref-type="table-fn"}   Revascularization (CABG 7, PCI 7)   Medication[\*](#tf3-2){ref-type="table-fn"}
  Clinical outcomes                                                                                                                                                                                                                                                                                                                                         
  Death, n (%)                   7 (9.6)               9 (6.5)                                       1                     0                                             3 (5)                                     3 (4)        4 (14.8)                                  0                                             0                                   3 (NC)
  Myocardial infarction, n (%)   0                     1                                             1                     0                                             1 (2)                                     4 (5)        1 (3.7)                                   0                                             0                                   0
  Revascularization, n (%)       4 (5.5)               17 (12.3)                                     2                     5                                             0                                         9 (11)       1 (3.7)                                   6 (25)[\*](#tf3-3){ref-type="table-fn"}       0                                   4

LMCA indicates left main coronary artery; FFR, fractional flow reserve; CABG indicates coronary artery bypass grafting; PCI, percutaneous coronary intervention; NC, noncardiac death.

Individualized decision was recommended on the basis of additional clinical data if FFR was 0.75 to 0.80.

Medical treatment or PCI elsewhere in the coronary tree.

\<0.05.

Conceptual Limitations of FFR in Intermediate LMCA Stenosis and a Practical Approach
====================================================================================

FFR measurement of intermediate ostial and shaft stenosis of LMCA provides accurate information about the functional status of angiographic intermediate stenosis ([Figure 2](#fig02){ref-type="fig"}A). However, many physicians have raised questions about the reliability of FFR measurement for the intermediate bifurcation stenosis of LMCA, as they consider the distal LMCA bifurcation as the tandem lesion interposing the large side branch.^[@b34]--[@b35]^ Therefore, FFR of intermediate LMCA stenosis tends to be under‐ or overestimated because of additional disease in the left anterior descending artery (LAD) and left circumflex artery (LCX) ([Figure 2](#fig02){ref-type="fig"}B); thereby, accurate assessment of functional status of intermediate LMCA stenosis itself would not be possible. However, this is only a conceptual limitation. Determining the functional significance and planning for treatment strategy are different issues. Recent IVUS analysis demonstrated the diffuse nature of atherosclerosis involving both the parent (LMCA) segment and both flow dividers (LAD and LCX).^[@b36]^ Atherosclerotic plaques extend from the LMCA to the LAD in 90% of patients and LCX in 62% of patients, which suggests distal LMCA bifurcation could not be treated separately and considered as a "single disease unit" ([Figure 2](#fig02){ref-type="fig"}C). Therefore, if both FFRs of LAD and LCX side are \>0.80, distal LMCA bifurcation is functionally insignificant. If any FFR of LAD and LCX side is ≤0.80, practically, distal LMCA bifurcation PCI as suggested below should be considered, without consideration of the functional significance of intermediate stenosis of the LMCA.

![Practical approach for the evaluation of functional significance of left main coronary artery stenosis. LAD indicates left anterior descending artery; LCX, left circumflex artery.](jah3-1-e004556-g2){#fig02}

Another reason why the FFR of intermediate LMCA stenosis should be interpreted with caution is that isolated LMCA stenoses are very rare, with most stenoses associated with disease in the LAD and/or LCX, both of which tend to increase FFR measured across the LMCA stenosis. Therefore, in this case, the reassessment for the functional significance of intermediate LMCA stenosis is recommended after the correction of distal coronary artery stenosis.

Complementary Roles of Intravascular Ultrasound in Functional Evaluation of LMCA Stenosis
=========================================================================================

Because of the limitations of the conventional coronary angiogram in assessing the severity of LMCA stenosis, there have been several attempts to compare the anatomical parameter assessed by intravascular ultrasound (IVUS) with the corresponding FFR measurement.

Jasti et al^[@b33]^ reported that an MLA of 5.9 mm^2^ had the highest sensitivity and specificity (93% and 95%, respectively) for determining a significant LM stenosis, compared with FFR as the gold standard. Recently, clinical application of an MLA criterion for treatment decision making for intermediate LMCA stenosis was tested.^[@b37]^ In the LITRO study, a total of 354 patients with intermediate LMCA stenoses were enrolled. In patients with an MLA\<6 mm^2^, revascularization were performed, and in patients with an MLA≥6 mm^2^, revascularization was deferred. In a 2‐year follow‐up period, there were no statistical between‐group differences regarding the incidence of death (2.3% versus 4.5%, respectively; *P*=0.5) and any event (12.7% versus 19.4%, respectively; *P*=0.3). Therefore, they suggested an MLA ≥6 mm^2^ was a safe value for deferring revascularization of the LMCA.

We recently addressed these issues in 55 patients with isolated intermediate LMCA stenosis who underwent preinterventional IVUS and FFR measurements to determine the IVUS MLA criterion corresponding to an FFR\<0.80.^[@b38]^ We found that the IVUS MLA value within the LMCA that best predicted FFR\<0.80 was \<4.8 mm^2^ (89% sensitivity, 83% specificity, 86% accuracy; AUC 0.90, 95% CI 0.788 to 0.964, *P*\<0.001). It is interesting to note that that the positive predictive value of IVUS‐measured MLA\<4.8 mm^2^ is acceptably high at 82%, in contrast with non‐LMCA stenosis ([Figure 3](#fig03){ref-type="fig"}).^[@b38]^ This might be explained by the simplicity of morphological characteristics of pure LM lesions, uniformly large vessel size, short lesion length, and lack of side branch and other anatomical factors that could potentially affect FFR. Therefore, in the evaluation of intermediate LMCA stenosis, anatomical parameter provided by IVUS appeared to be correlated well with functional significance of LMCA stenosis.

![Correlation between minimal lumen area and fractional flow reserve in intermediate left main coronary artery stenosis. FFR indicates fractional flow reserve. With permission from Kang et al.^[@b38]^](jah3-1-e004556-g3){#fig03}

How to Perform Unprotected LMCA Stenting
========================================

From a technical perspective, it would be easy to perform a single‐stent procedure for ostial and shaft LM disease; published long‐term clinical outcomes are excellent.^[@b39]--[@b41]^ The current PCI guideline was updated as mentioned before.^[@b23]--[@b24]^ For LMCA bifurcation disease, unresolved technical issues remain. The single‐stent technique clearly shows more favorable long‐term clinical outcomes compared with the 2‐stent technique, even in bifurcation LM disease.^[@b42]--[@b45]^ Therefore, in real practice, the single‐stent crossover technique has been used more frequently, in as many as ≈60% of all LMCA bifurcation treatments.^[@b42]^ Selection of a single‐ or 2‐stent technique should be based on disease involvement of the LCX ostium, because side‐branch compromise after stent crossover is frequent in the setting of significant ostial disease of the side branch ([Table 4](#tbl04){ref-type="table"}). Thus, to determine the choice of a single‐ or 2‐stent strategy, IVUS provides accurate information for both main‐ and side‐branch disease status and vascular remodeling in LMCA bifurcation lesions. In addition, if possible, direct imaging from the LCX is necessary for accurate assessment of the side branch, including its ostium, because IVUS evaluation of a side‐branch ostium from the main vessel is only moderately reliable.^[@b46]^

###### 

Favorable or Unfavorable Anatomical Features for Single‐Stent Crossover Stenting in Treatment of Unprotected Left Main Coronary Artery Stenosis^[@b54]^

                                                                              Anatomical Features
  --------------------------------------------------------------------------- --------------------------------------------------------------------------------------------
  Favorable                                                                   Insignificant stenosis at the ostial LCX with Medina classification 1,1,0 or 1,0,0
  Diminutive LCX with \<2.5 mm in diameter; right dominant coronary system    
  Wide angle with LAD                                                         
  No concomitant disease in LCX                                               
  Focal disease in LCX                                                        
  Unfavorable                                                                 Insignificant stenosis at the ostial LCX with Medina classification 1,1,1; 1,0,1; or 0,1,1
  Large size of LCX with ≥2.5 mm in diameter; left dominant coronary system   
  Narrow angle with LAD                                                       
  Concomitant disease in LCX                                                  
  Diffuse disease in LCX                                                      

LCX indicates left circumex artery; LAD, left anterior descending artery.

Table is adapted with permission from Moussa et al.[@b54]

After main‐stent crossover from the proximal left anterior descending artery (LAD) to LM, geometric changes in the LCX ostium were related mainly to carina shift, reduction of MLA, and increased eccentricity of the external elastic membrane and carina angle between the LAD and the LCX ([Figure 4](#fig04){ref-type="fig"}).^[@b47]^ However, an important issue is being unable to predict the functional significance of the stenosis with only the degree of jailed LCX ostium, no matter how big or small. Therefore, in cases in which the LCX ostium is significantly compromised (\>50%) after simple crossover stent implantation from LM to LAD, we should consider FFR measurement first before further treatment of the LCX.

![Geometric changes in left main coronary artery bifurcation after main‐branch stenting. Longitudinal image reconstruction demonstrated carina shift into the LCX poststenting (arrow). EEM indicates external elastic membrane; P+M, plaque area plus media area; LAD, left anterior descending artery; LCX, left circumflex artery. Adapted with permission from Kang et al.^[@b47]^](jah3-1-e004556-g4){#fig04}

IVUS Minimal Stent Area Criteria Optimizing the Clinical Outcomes
=================================================================

Optimal stent expansion was considered one of the most important factors in preventing restenosis or adverse clinical outcomes.^[@b48]--[@b49]^ However, there are no data suggesting the optimal minimal stent area (MSA) cutoff for prediction of restenosis and long‐term clinical outcome after DES implantation for LMCA stenosis.

Recently, we studied the optimal IVUS‐MSA criteria for prevention of in‐stent restenosis (ISR) in 403 patients undergoing sirolimus‐eluting stent implantation for LMCA disease.^[@b50]^ We classified the LMCA into 4 segments: the LCX ostium, LAD ostium, polygon of confluence (POC), and LMCA above the POC. The best IVUS‐MSA criteria that predicted angiographic ISR on a segmental basis were 5.0 mm^2^ for the LCX ostium, 6.3 mm^2^ for the LAD ostium, 7.2 mm^2^ for the POC, and 8.2 mm^2^ for the proximal LMCA above the POC ([Figure 5](#fig05){ref-type="fig"}).^[@b50]^ Using these criteria, 133 patients (33.8%) experienced underexpansion ≥1 of the prespecified segments. In addition, underexpansion was more frequent in the 2‐stent group than in the single‐stent group (54% versus 27%, respectively, *P*=0.001). In the 2‐stent group, the LCX ostium was the most common site of underexpansion (37%), which may explain the greater risk of ISR when LMCA bifurcation lesions are treated with a 2‐stent strategy. Overall, angiographic ISR was more frequent in lesions with underexpansion than in lesions without underexpansion (24.1% versus 5.4%, respectively; *P*=0.001). Even in the 2‐stent group, lesions with complete expansion at all sites showed only 6% of the ISR rate, which was similar to that of the single‐stent group (6.3%) or in nonbifurcation LMCA lesions (4.5%). Furthermore, a smaller IVUS‐MSA predicted angiographic ISR 9 months after DES implantation for treatment of LMCA disease, and poststenting underexpansion was an independent predictor of 2‐year adverse clinical outcomes, especially repeat revascularization.

![Cutoff values of minimal stent area for the prediction of angiographic in‐stent restenosis on a segmental basis. LM indicates left main; POC, polygon of confluence; LAD, left anterior descending artery; LCX, left circumflex artery. Adapted with permission from Kang et al.^[@b50]^](jah3-1-e004556-g5){#fig05}

Impact of IVUS Guidance for LMCA Stenting
=========================================

Although IVUS guidance has been useful in stenting unprotected LMCA stenoses, its impact on long‐term mortality is still unclear. In 201 matched pairs from the MAIN‐COMPARE registry, there was a tendency of lower risk for 3‐year mortality with IVUS guidance compared with angiography guidance (6.0% versus 13.6%, respectively; log‐rank *P*=0.063; hazard ratio 0.54).^[@b26]^ In particular, for 145 matched pairs of patients receiving DES, the 3‐year mortality was significantly lower for IVUS guidance compared with angiography guidance (4.7% versus 16.0%, respectively; log‐rank *P*=0.048; hazard ratio 0.39). It is interesting to note that the mortality rate started to diverge beyond 1 year after the procedure. In contrast, the use of IVUS did not reduce the risk of mortality in 47 matched pairs of patients receiving a bare‐metal stent (8.6% versus 10.8%, respectively; log‐rank *P*=0.35; hazard ratio 0.59). Therefore, despite inherent limitations of nonrandomized registry design, this study indicated that IVUS guidance may play a role in reducing very late stent thrombosis and subsequent long‐term mortality.

IVUS guidance has provided more information on negative remodeling, reference vessel size, and morphologic complexity of ostial or bifurcation lesions in preintervention evaluation, stent underexpansion, incomplete lesion coverage, small stent area, large residual plaque, and incomplete stent apposition in postinterventional evaluation.^[@b51]--[@b53]^ For LMCA lesions, in particular, the use of IVUS is helpful in determining treatment strategy and in optimizing the stent procedure. Therefore, we strongly recommend mandatory use of IVUS in PCI for unprotected LMCA.

Conclusions
===========

FFR‐guided PCI can help to select appropriate patients and lesions for treatment, avoid unnecessary procedures, reduce medical costs, and improve clinical outcomes. Furthermore, IVUS can be used to secure the PCI procedure by preinterventional lesion assessment and postinterventional stent optimization. We propose the concept of the integrated use of FFR and IVUS in LMCA stenting ([Figure 6](#fig06){ref-type="fig"}). Despite several limitations of this approach including cost, procedural time, and availability of trained personnel, FFR‐guided complex PCI, which is supported by IVUS, can give us better insights into LMCA disease and may improve the clinical outcomes of patients who undergo LMCA stenting.

![Integrated use of FFR and IVUS in left main stenting. LMCA indicates left main coronary artery; FFR, fractional flow reserve; IVUS, intravascular ultrasound; MLA, minimal lumen area; MSA, minimal stent area.](jah3-1-e004556-g6){#fig06}
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